Literature DB >> 2165544

Endocrine activity of the "silent" adrenocortical adenoma is uncovered by response to corticotropin-releasing hormone.

J Hensen1, M Buhl, V Bähr, W Oelkers.   

Abstract

The purpose of this study was to ascertain whether the pituitary-adrenal responses to human corticotropin-releasing hormone (hCRH) in "non-functioning" adrenocortical adenoma would uncover a functional activity in these adrenal nodules. Eleven patients with incidentally discovered "silent" adrenocortical adenoma and eleven controls were studied. The initial clinical and laboratory examination, including an overnight 1 mg dexamethasone suppression test, revealed no abnormalities in any of the subjects. IR-ACTH and serum steroids (F, S, P, 17OHP, 18OHB, and aldosterone) were normal in both controls and patients. After pulse IV injection of 100 micrograms hCRH, the cortisol response was significantly exaggerated (P = 0.01). Stimulated plasma ACTH levels were, however, significantly lower in patients than in controls (P = 0.01), indicating counter-feedback regulation of cortisol. The peak cortisol/peak ACTH ratio (Fmax/ACTHmax) in the patients was significantly elevated (26.8 +/- 4.37 nmol/ng vs. 14.6 +/- 2.16 nmol/ng, P = 0.02). Two further patients with incidentally discovered "pre-Cushing's" adrenocortical adenoma displayed an even higher ratio (43.5 and 45.5 nmol/ng). In established Cushing's syndrome due to an autonomous adrenocortical adenoma, suppression of ACTH and of the ACTH response to hCRH occurs with a very high basal cortisol/basal ACTH ratio. Our findings suggest some functional activity even in clinically "silent" adrenocortical adenoma. Response to hCRH uncovers a continuous spectrum between adrenocortical adenoma, "pre-Cushing's", and Cushing's syndrome.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2165544     DOI: 10.1007/BF01660959

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  31 in total

1.  Ability of corticotropin releasing hormone to stimulate cortisol secretion independent from pituitary adrenocorticotropin.

Authors:  H L Fehm; R Holl; E Späth-Schwalbe; J Born; K H Voigt
Journal:  Life Sci       Date:  1988       Impact factor: 5.037

2.  On the prevalence of adrenocortical adenomas in an autopsy material in relation to hypertension and diabetes.

Authors:  H Hedeland; G Ostberg; B Hökfelt
Journal:  Acta Med Scand       Date:  1968-09

Review 3.  The incidentally discovered adrenal mass.

Authors:  P M Copeland
Journal:  Ann Intern Med       Date:  1983-06       Impact factor: 25.391

4.  Adrenal cortex dysfunction: CT findings.

Authors:  K H Huebener; H Treugut
Journal:  Radiology       Date:  1984-01       Impact factor: 11.105

5.  Management of the adrenal "incidentaloma".

Authors:  G W Geelhoed; E M Druy
Journal:  Surgery       Date:  1982-11       Impact factor: 3.982

6.  Steroid biosynthesis in human adrenal tumors.

Authors:  R D'Agata; S Malozowski; A Barkan; F Cassorla; D Loriaux
Journal:  Horm Metab Res       Date:  1987-08       Impact factor: 2.936

7.  Effects of incremental infusions of arginine vasopressin on adrenocorticotropin and cortisol secretion in man.

Authors:  J Hensen; O Hader; V Bähr; W Oelkers
Journal:  J Clin Endocrinol Metab       Date:  1988-04       Impact factor: 5.958

8.  Effects of angiotensin II and ACTH on normal and tumourous human adrenocortical cells.

Authors:  W Belmega; W Oelkers; L Belkien; M Shirpai; U Fiedler; R Häring
Journal:  Acta Endocrinol (Copenh)       Date:  1983-09

9.  The corticotropin-releasing factor stimulation test. An aid in the evaluation of patients with Cushing's syndrome.

Authors:  G P Chrousos; H M Schulte; E H Oldfield; P W Gold; G B Cutler; D L Loriaux
Journal:  N Engl J Med       Date:  1984-03-08       Impact factor: 91.245

10.  Proopiocortin-related peptide plasma levels throughout prepuberty and puberty.

Authors:  A R Genazzani; F Facchinetti; C Pintor; R Puggioni; D Parrini; F Petraglia; F Bagnoli; R Corda
Journal:  J Clin Endocrinol Metab       Date:  1983-07       Impact factor: 5.958

View more
  7 in total

1.  Endocrinological and pathological entities of the pre-Cushing's syndrome.

Authors:  Y Kubota; T Nakada; I Sasagawa; T Izumi; M Ishigooka; T Nishikawa; K Kawai
Journal:  Int Urol Nephrol       Date:  1998       Impact factor: 2.370

Review 2.  The clinical evaluation of silent adrenal masses.

Authors:  B Ambrosi; E Passini; T Re; L Barbetta
Journal:  J Endocrinol Invest       Date:  1997-02       Impact factor: 4.256

3.  Pre-Cushing's syndrome not recognized by conventional dexamethasone suppression-tests in an adrenal "incidentaloma" patient.

Authors:  M Torlontano; M Zingrillo; L D'Aloiso; M R Ghiggi; A Di Cerbo; A Scillitani; G Petracca-Ciavarella; A Liuzzi
Journal:  J Endocrinol Invest       Date:  1997-09       Impact factor: 4.256

4.  Comparative analysis of plasma 17-hydroxyprogesterone and cortisol responses to ACTH in patients with various adrenal tumors before and after unilateral adrenalectomy.

Authors:  M Tóth; K Rácz; V Adleff; I Varga; L Fütö; C Jakab; K Karlinger; R Kiss; E Gláz
Journal:  J Endocrinol Invest       Date:  2000-05       Impact factor: 4.256

5.  Cardiovascular risk in patients with nonfunctional adrenal incidentaloma: myth or reality?

Authors:  Yesim Erbil; Nese Ozbey; Umut Barbaros; Haluk Recai Unalp; Artur Salmaslioglu; Selçuk Ozarmagan
Journal:  World J Surg       Date:  2009-10       Impact factor: 3.352

6.  Conservative and surgical management of incidentally discovered adrenal tumors (incidentalomas).

Authors:  F Jockenhövel; W Kuck; B Hauffa; W Reinhardt; G Benker; S Lederbogen; T Olbricht; D Reinwein
Journal:  J Endocrinol Invest       Date:  1992-05       Impact factor: 4.256

7.  Long-term morphological and hormonal follow-up in a single unit on 115 patients with adrenal incidentalomas.

Authors:  G P Bernini; A Moretti; C Oriandini; M Bardini; C Taurino; A Salvetti
Journal:  Br J Cancer       Date:  2005-03-28       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.